Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma

The NovoTTF-100A device emits frequency-tuned alternating electric fields that interfere with tumor cell mitosis. In phase III trial for recurrent glioblastomas, NovoTTF-100A was shown to have equivalent efficacy and less toxicity when compared to Best Physician's Choice (BPC) chemotherapy. We...

Descrición completa

Gardado en:
Detalles Bibliográficos
Main Authors: Wong, Eric T, Lok, Edwin, Swanson, Kenneth D, Gautam, Shiva, Engelhard, Herbert H, Lieberman, Frank, Taillibert, Sophie, Ram, Zvi, Villano, John L
Formato: Artigo
Idioma:Inglês
Publicado: BlackWell Publishing Ltd 2014
Assuntos:
Original Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4101750/
https://ncbi.nlm.nih.gov/pubmed/24574359
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.210
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares